{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T16:07:38Z","timestamp":1794413258510,"version":"4.9.1"},"reference-count":40,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"unspecified","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Marie Sklodowska-Curie","award":["754425"],"award-info":[{"award-number":["754425"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2022,12,27]]},"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are age-associated inflammatory diseases that frequently overlap. Both diseases require long-term treatment with glucocorticoids (GCs), often associated with comorbidities. Previous population-based cohort studies reported that an unhealthier metabolic profile might prevent the development of GCA. Here, we report metabolic features before start of treatment and during treatment in patients with GCA and PMR.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In the Dutch GCA\/PMR\/SENEX (GPS) cohort, we analysed metabolic features and prevalence of comorbidities (type 2 diabetes, hypercholesterolaemia, hypertension, obesity and cataract) in treatment-na\u00efve patients with GCA (n=50) and PMR (n=42), and compared those with the population-based Lifelines cohort (n=91). To compare our findings in the GPS cohort, we included data from patients with GCA (n=52) and PMR (n=25) from the Aarhus cohort. Laboratory measurements, comorbidities and GC use were recorded for up to 5\u2009years in the GPS cohort.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Glycated haemoglobin levels tended to be higher in treatment-na\u00efve patients with GCA, whereas high-density lipoprotein, low-density lipoprotein and cholesterol levels were lower compared with the Lifelines population. Data from the Aarhus cohort were aligned with the findings obtained in the GPS cohort. Presence of comorbidities at baseline did not predict long-term GC requirement. The incidence of diabetes, obesity and cataract among patients with GCA increased upon initiation of GC treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Data from the GCA and PMR cohorts imply a metabolic dysregulation in treatment-na\u00efve patients with GCA, but not in patients with PMR. Treatment with GCs led to the rise of comorbidities and an unhealthier metabolic profile, stressing the need for prednisone-sparing targeted treatment in these vulnerable patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2022-002640","type":"journal-article","created":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T10:52:30Z","timestamp":1673434350000},"page":"e002640","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":15,"title":["Metabolic features and glucocorticoid-induced comorbidities in patients with giant cell arteritis and polymyalgia rheumatica in a Dutch and Danish cohort"],"prefix":"10.1136","volume":"9","author":[{"given":"Idil","family":"Esen","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4422-7640","authenticated-orcid":false,"given":"Suzanne","family":"Arends","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berit","family":"Dalsgaard Nielsen","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark"},{"name":"Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Therkildsen","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark"},{"name":"Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ib","family":"Hansen","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark"},{"name":"Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"van 't Ende","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8684-763X","authenticated-orcid":false,"given":"Peter","family":"Heeringa","sequence":"additional","affiliation":[{"name":"Department of Pathology and Medical Biology, University Medical Center Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemieke","family":"Boots","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Hauge","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark"},{"name":"Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4809-0653","authenticated-orcid":false,"given":"Elisabeth","family":"Brouwer","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7382-8322","authenticated-orcid":false,"given":"Yannick","family":"van Sleen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,1,11]]},"reference":[{"key":"2025090313123807000_9.1.e002640.1","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.40520","article-title":"Review: what is the current evidence for disease subsets in giant cell arteritis?","volume":"70","author":"van der Geest","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2025090313123807000_9.1.e002640.2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew273"},{"key":"2025090313123807000_9.1.e002640.3","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-019-1389-3"},{"key":"2025090313123807000_9.1.e002640.4","doi-asserted-by":"crossref","first-page":"105045","DOI":"10.1016\/j.jbspin.2020.06.018","article-title":"Aortic involvement in giant cell arteritis","volume":"88","author":"Carvajal Alegria","year":"2021","journal-title":"Joint Bone Spine"},{"key":"2025090313123807000_9.1.e002640.5","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s40266-019-00705-5","article-title":"Pathogenesis, diagnosis and management of polymyalgia rheumatica","volume":"36","author":"Camellino","year":"2019","journal-title":"Drugs Aging"},{"key":"2025090313123807000_9.1.e002640.6","doi-asserted-by":"publisher","DOI":"10.2217\/ahe.11.50"},{"key":"2025090313123807000_9.1.e002640.7","first-page":"270","article-title":"Developing classification criteria for polymyalgia rheumatica: comparison of views from an expert panel and wider survey","volume":"35","author":"Dasgupta","year":"2008","journal-title":"J Rheumatol"},{"key":"2025090313123807000_9.1.e002640.8","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1093\/rheumatology\/keaa080","article-title":"Negative associations for fasting blood glucose, cholesterol and triglyceride levels with the development of giant cell arteritis","volume":"59","author":"Wadstr\u00f6m","year":"2020","journal-title":"Rheumatology"},{"key":"2025090313123807000_9.1.e002640.9","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu331"},{"key":"2025090313123807000_9.1.e002640.10","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/03009742.2018.1506821","article-title":"Cardiovascular risk factors and incident giant cell arteritis: a population-based cohort study","volume":"48","author":"Tomasson","year":"2019","journal-title":"Scand J Rheumatol"},{"key":"2025090313123807000_9.1.e002640.11","first-page":"1","article-title":"Lower body mass index is associated with a higher risk of giant cell arteritis: a systematic review and meta-analysis","volume":"3","author":"Ungprasert","year":"2015","journal-title":"Ann Transl Med"},{"key":"2025090313123807000_9.1.e002640.12","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkaa013"},{"key":"2025090313123807000_9.1.e002640.13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1756-185X.2010.01527.x"},{"key":"2025090313123807000_9.1.e002640.14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq039a"},{"key":"2025090313123807000_9.1.e002640.15","doi-asserted-by":"crossref","first-page":"ii11","DOI":"10.1093\/rheumatology\/kex459","article-title":"Prevention of glucocorticoid morbidity in giant cell arteritis","volume":"57","author":"Buttgereit","year":"2018","journal-title":"Rheumatology"},{"key":"2025090313123807000_9.1.e002640.16","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.semarthrit.2016.11.002","article-title":"Newly diagnosed vs. relapsing giant cell arteritis: baseline data from the GiACTA trial","volume":"46","author":"Tuckwell","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2025090313123807000_9.1.e002640.17","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.semarthrit.2016.10.001","article-title":"Incidence of outcomes potentially associated with corticosteroid therapy in patients with giant cell arteritis","volume":"46","author":"Wilson","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2025090313123807000_9.1.e002640.18","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.semarthrit.2016.11.006","article-title":"Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): a nested case-control analysis","volume":"46","author":"Wilson","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2025090313123807000_9.1.e002640.19","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s40744-019-00180-9","article-title":"Risk of potential glucocorticoid-related adverse events in patients with giant cell arteritis: results from a USA-based electronic health records database","volume":"6","author":"Best","year":"2019","journal-title":"Rheumatol Ther"},{"key":"2025090313123807000_9.1.e002640.20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/rmdopen-2017-000521","article-title":"Association between glucocorticoid therapy and incidence of diabetes mellitus in polymyalgia rheumatica and giant cell arteritis: a systematic review and meta-analysis","volume":"4","author":"Lai","year":"2018","journal-title":"RMD Open"},{"key":"2025090313123807000_9.1.e002640.21","doi-asserted-by":"publisher","DOI":"10.1002\/art.11388"},{"key":"2025090313123807000_9.1.e002640.22","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.semarthrit.2016.05.009","article-title":"Corticosteroid-related adverse events in patients with giant cell arteritis: a claims-based analysis","volume":"46","author":"Broder","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"2025090313123807000_9.1.e002640.23","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1210\/jc.2017-01133","article-title":"Associations between systemic and local corticosteroid use with metabolic syndrome and body mass index","volume":"102","author":"Savas","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"2025090313123807000_9.1.e002640.24","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2020-001220"},{"key":"2025090313123807000_9.1.e002640.25","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110851"},{"key":"2025090313123807000_9.1.e002640.26","doi-asserted-by":"crossref","first-page":"e886","DOI":"10.1016\/S2665-9913(21)00277-0","article-title":"Disease stratification in giant cell arteritis to reduce relapses and prevent long-term vascular damage","volume":"3","author":"Tomelleri","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2025090313123807000_9.1.e002640.27","doi-asserted-by":"publisher","DOI":"10.1002\/art.34356"},{"key":"2025090313123807000_9.1.e002640.28","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00259-018-4021-4","article-title":"Three days of high-dose glucocorticoid treatment attenuates large-vessel 18F-FDG uptake in large-vessel giant cell arteritis but with a limited impact on diagnostic accuracy","volume":"45","author":"Nielsen","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2025090313123807000_9.1.e002640.29","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyu229"},{"key":"2025090313123807000_9.1.e002640.30","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3109\/14397595.2015.1081722","article-title":"Patients with giant cell arteritis have a lower prevalence of diabetes mellitus: a systematic review and meta-analysis","volume":"26","author":"Ungprasert","year":"2016","journal-title":"Mod Rheumatol"},{"key":"2025090313123807000_9.1.e002640.31","first-page":"68","article-title":"A study on physiological changes in essential hypertension and rheumatoid arthritis with reference to the levels of cortisol, blood glucose, triglycerides and cholesterol","volume":"39","author":"Mishra","year":"1995","journal-title":"Indian J Physiol Pharmacol"},{"key":"2025090313123807000_9.1.e002640.32","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13075-021-02476-0","article-title":"Impact of disease activity on impaired glucose metabolism in patients with rheumatoid arthritis","volume":"23","author":"Risti\u0107","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2025090313123807000_9.1.e002640.33","doi-asserted-by":"crossref","unstructured":"Esen I , Jiemy WF , van Sleen Y . Plasma pyruvate kinase M2 as a marker of vascular inflammation in giant cell arteritis. Rheumatology 2021.doi:10.1093\/rheumatology\/keab814","DOI":"10.1093\/rheumatology\/keab814"},{"key":"2025090313123807000_9.1.e002640.34","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41584-019-0256-0","article-title":"Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions","volume":"15","author":"Ferguson","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"2025090313123807000_9.1.e002640.35","doi-asserted-by":"crossref","first-page":"101562","DOI":"10.1016\/j.berh.2020.101562","article-title":"The impact of lifestyle behaviours, physical activity and smoking on morbidity and mortality in patients with rheumatoid arthritis","volume":"34","author":"Gwinnutt","year":"2020","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2025090313123807000_9.1.e002640.36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms151222279"},{"key":"2025090313123807000_9.1.e002640.37","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.semarthrit.2018.07.001","article-title":"Smoking as a risk factor for giant cell arteritis: a systematic review and meta-analysis","volume":"48","author":"Brennan","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"2025090313123807000_9.1.e002640.38","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.039404"},{"key":"2025090313123807000_9.1.e002640.39","doi-asserted-by":"crossref","unstructured":"Scott IC , Bajpai R , Hider SL , et al . O38\u2003The relationship between obesity and outcomes in patients with polymyalgia rheumatica. Rheumatology 2020;59.doi:10.1093\/rheumatology\/keaa110.037","DOI":"10.1093\/rheumatology\/keaa110.037"},{"key":"2025090313123807000_9.1.e002640.40","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102692","article-title":"Impact of age at diagnosis in polymyalgia rheumatica: a retrospective cohort study of 218 patients","volume":"19","author":"Van Hemelen","year":"2020","journal-title":"Autoimmun Rev"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2022-002640","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:12:46Z","timestamp":1756930366000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2022-002640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1,11]]},"published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1136\/rmdopen-2022-002640"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2022-002640","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]}}}